Company profile
Merck & Company, Inc. logo

Merck & Company, Inc.

Pipeline9 assets

Latest news25 items

All news

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

First and only PD-1 inhibitor plus antibody-drug conjugate regimens approved for patients with MIBC regardless of cisplatin eligibility Approvals based on Phase 3 KEYNOTE-B15 trial, combined with previous approvals based on Phase 3 KEYNOTE-905 trial, bring forward new options for these patients RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter....

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

First approval of PD‑1 inhibitors in combination with a Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S....

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Approval based on results from the Phase 3 KEYNOTE-905 trial in which perioperative KEYTRUDA plus Padcev reduced the risk of event-free survival events by 60% and risk of death by 50% versus surgery alone in these patients RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a Phase 3 trial Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in inflammatory bowel disease (IBD) and other immune-mediated inflammatory conditions RAHWAY,...

Trial Results • Phase 3Results event Wed, Dec 31, 2025

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

CAPVAXIVE is the only Pneumococcal Conjugate Vaccine (PCV) specifically indicated and studied in the U.S. for use in this population CAPVAXIVE, when added to existing primary pediatric pneumococcal vaccination series, helps deliver additional protection by including serotypes not contained in approved primary pediatric PCV series RAHWAY, N.J.–(BUSINESS...

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Marks the first approved combinations of a PD-1 and HIF-2α inhibitor Approvals based on Phase 3 LITESPARK-022 trial that showed KEYTRUDA in combination with WELIREG reduced the risk of disease recurrence, metastasis or death by 28% compared to KEYTRUDA plus placebo Represents the first and only global Phase 3 study to have demonstrated an improvement in...

Merck Animal Health to Acquire TARGAN

TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScanTM, delivers enhanced poultry performance RAHWAY, N.J., June 11, 2026 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has...

Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Multiple Mechanisms of Action, including Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle – – Islatravir/Lenacapavir has the Potential to be the First Approved...

Trial Results • Phase 3Topline results Mon, Jun 8, 2026, 4:39 PM EDT

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

RAHWAY, N.J. & FOSTER CITY, Calif.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy ® (sacituzumab govitecan-hziy) in combination with KEYTRUDA ® (pembrolizumab),...

Trial Results • Phase 3Results event Wed, Dec 31, 2025

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone Intismeran autogene in combination with KEYTRUDA...

Presentation / Abstract • Phase 2ASCO presentation Mon, Jun 1, 2026, 8:00 AM EDT

Merck to Participate in the Jefferies Global Healthcare Conference

RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4,...

Merck Announces Third-Quarter 2026 Dividend

RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the third quarter of 2026....

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Opinion granted based on positive event-free survival, overall survival and pathologic complete response rate results from the Phase 3 KEYNOTE-905 trial If approved, this combination would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen for this patient population in the European Union RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

Sac-TMT is the first TROP2 ADC to improve OS and PFS compared to chemotherapy in patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and anti-PD-1/L1 immunotherapy in a global Phase 3 study RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Trial Results • Phase 3Results event Wed, Dec 31, 2025

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Five-year follow-up data from KEYNOTE-942 underscore the continued potential of intismeran autogene (mRNA-4157 or V940) in combination with KEYTRUDA ® (pembrolizumab) for patients with resected high-risk melanoma Results from the final analysis of KEYNOTE-522, evaluating KEYTRUDA in combination with chemotherapy, demonstrate continued survival benefit for...

Presentation / Abstract • Phase 3ASCO abstract release Fri, May 29, 2026

Merck Statement on Daiichi Sankyo Update to Manufacturing and Supply Plan

RAHWAY, N.J., May 08, 2026 – We are aware of Daiichi Sankyo’s update to its manufacturing and supply plan for its antibody drug conjugate (ADC) products and candidates. We have previously reserved for the portion of these charges related to the ADCs being developed as part of our collaboration with Daiichi Sankyo;...

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq:...

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX 1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million WINREVAIR Sales Were $525 Million (88% Growth;...

Merck & Company, Inc. • Endpoint Arena